Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

Tesamorelin

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue approved for reducing visceral fat in HIV-associated lipodystrophy, with evidence supporting its efficacy in improving body composition and metabolic profiles.

fat-lossbody-compositionmetabolicgrowth-hormone

Evidence last reviewed: 19 Apr 2026

Buy this ingredient ← Back

Supplement note

Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Biomarkers studied

Outcomes directly measured across the evidence records below

Cardiovascular

Triglycerides

Hormonal

IGF-1

Metabolic

Lean / Muscle MassBody Fat %

Cognitive

Cognitive Function

Evidence

5 records

Neurocognitive performance

HIV patients with abdominal obesity • RCT

PUBMEDModerate

Tesamorelin showed a trend towards improved neurocognitive performance, but the difference was not statistically significant.

Dose: 2000 mgDuration: 6 monthsForm: Subcutaneous injection

Citation: Stanley et al. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Journal.

Liver fat reduction

HIV patients with NAFLD • RCT

PUBMEDHigh

Tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD.

Dose: 2000 mgDuration: 12 monthsForm: Subcutaneous injection

Citation: Fraile et al. (2021). Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Journal.

Muscle area increase

HIV patients with abdominal obesity • RCT

PUBMEDModerate

Tesamorelin decreased muscle fat and increased muscle area.

Dose: 2000 mgDuration: 6 monthsForm: Subcutaneous injection

Citation: Adrian et al. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. Journal.

IGF-1 increase

HIV patients with abdominal fat accumulation • RCT

PUBMEDHigh

Tesamorelin increased IGF-1 levels, which may contribute to its effects on body composition.

Dose: 2000 mgDuration: Long-termForm: Subcutaneous injection

Citation: Falutz et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. Journal.

Visceral fat reduction

HIV patients with abdominal fat accumulation • RCT

PUBMEDHigh

Tesamorelin significantly reduced visceral fat and hepatic fat in HIV patients.

Dose: 2000 mgDuration: 12 monthsForm: Subcutaneous injection

Citation: Fourman et al. (2021). Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Journal.

Forms

Subcutaneous injection

Typically administered as a daily injection.

Stacks containing Tesamorelin

Public community stacks that include this ingredient.

Explore all stacks →

No public stacks include this ingredient yet.